


ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.P./



Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60390-1A/JPW/GJG/ML		Serial No. 10/718,280								
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicants: Arlindo L. Castelhana et al.										
				Filing Date November 20, 2003		Group 1624								
U.S. PATENT DOCUMENTS														
Examiner Initial		Document Number							Date	Name	Class	Subclass	Filing Date if Appropriate	
	1	5	2	9	6	4	8	4	3/22/94	Coghlan et al.				
	2	5	6	4	6	1	3	0	7/8/97	Shi				
	3	5	8	7	7	1	8	0	3/2/99	Linden et al.				
	4	5	8	8	9	0	2	6	3/30/99	Alanine et al.				
	5	5	9	3	5	9	6	4	8/10/99	Baraldi et al.				
	6	6	1	1	7	8	7	8	9/12/00	Linden				
	7	6	4	6	5	4	5	6	10/15/02	Springer et al.				
	8	6	9	1	6	8	0	4	7/12/05	Castelhana et al.				
	9	7	2	0	2	2	5	2	4/10/07	Wilson et al.				
	10	20	03	01	39	4	2	7	11/1/05	Castelhana et al.				
	11	20	03	02	29	0	6	7	12/11/03	Castelhana et al.				
	12	20	05	01	19	2	7	1	6/2/05	Castelhana et al.				
	13	20	04	00	82	5	9	9	4/29/04	Castelhana et al.				
	14	20	05	00	43	3	3	2	2/24/05	Castelhana et al.				
	15	20	08	00	70	9	3	6	3/20/08	Castelhana et al.				
FOREIGN PATENT DOCUMENTS														
		Document Number							Date	Country	Class	Subclass	Translation	
													Yes	No
	16	9	7	4	7	6	0	1	12/18/97	PCT				
	17	9	9	6	4	4	0	7	12/16/99	PCT				
	18	9	9	0	8	4	6	0	2/18/99	PCT				
	19	0	0	0	3	7	4	1	1/27/00	PCT				
	20	20	03	05	3	3	6	1	7/3/03	PCT				
	21	20	03	05	3	3	6	6	7/3/03	PCT				
	22	0	7	2	9	7	5	8	9/4/96	EPO				
	23	1	2	4	6	6	2	3	8/9/06	EPO				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
	24	Hungarian Patent No. HU P9303515 (corresponds to WO 94/13676)												
	25	Hungarian Patent No. HU P9501230 (corresponds to EP 0682027)												
	26	Hungarian Patent No. HU P9602016 (corresponds to WO 95/19970)												
	27	Hungarian Patent No. HU P9402829 (corresponds to WO 93/20078)												
	28	Hungarian Patent No. HU P9602017 (corresponds to WO 95/19774)												
	29	Abbracchio M., et al., (1997) "Modulation of Apoptosis by Nervous System: a Possible Role for the A3 Receptor", <i>Ann. NY. Acad. Sci.</i> , 825: 11-22												
	30	Aoyama S. et al. (2000) "Rescue of Locomotor Impairment in Dopamine D2 Receptor-Deficient Mice by an Adenosine A2a Receptor Antagonist" <i>J. Neuroscience</i> 20(15) : 5848-5852												
	31	Avila, M.Y. (2001) "A1-A2a and A3-Subtype Adenosine receptors Modulate Intraocular Pressure in the Mouse" <i>J. of Pharmacol.</i> 241-245												
	32	Baraldi, P.G. et al. (1996) "Pyrazolo [4,3-e]-1,2,4 triazolo [1,5-c]pyrimidine Derivatives: Potent and Selective A2a Adenosine Antagonists" <i>J. Med. Chem.</i> 39: 1164-1171												
	33	Baraldi P., et al. (2000) "New potent and selective human adenosine A3 receptor antagonists", <i>Tips</i> , 21: 456-459												
	34	Baraldi P., et al. "Pyrazolo-triazolo-pyrimidine derivatives as adenosine receptor antagonists: a possible template for adenosine receptor subtypes", <i>Curr. Pharm. Design</i> 8: 2299-2332, 2002												
EXAMINER		/Alton Pryor/							DATE CONSIDERED					
									10/20/2008					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

Applicants: Arlindo Castelhana et al.
Serial No.: 10/718,280
Filed: November 20, 2003
Exhibit A

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.P./

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60390-1A/JPW/GJG/ML		Serial No. 10/718,280	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicants: Arlindo L. Castelhana et al.			
					Filing Date November 20, 2003		Group 1624	
U.S. PATENT DOCUMENTS								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
	1	5 2 9 6 4 8 4	3/22/94	Coghlan et al.				
	2	5 6 4 6 1 3 0	7/8/97	Shi				
	3	5 8 7 7 1 8 0	3/2/99	Linden et al.				
	4	5 8 8 9 0 2 6	3/30/99	Alanine et al.				
	5	5 9 3 5 9 6 4	8/10/99	Baraldi et al.				
	6	6 1 1 7 8 7 8	9/12/00	Linden				
	7	6 4 6 5 4 5 6	10/15/02	Springer et al.				
	8	6 9 1 6 8 0 4	7/12/05	Castelhana et al.				
	9	7 2 0 2 2 5 2	4/10/07	Wilson et al.				
	10	20 03 01 39 4 2 7	11/1/05	Castelhana et al.				
	11	20 03 02 29 0 6 7	12/11/03	Castelhana et al.				
	12	20 05 01 19 2 7 1	6/2/05	Castelhana et al.				
	13	20 04 00 82 5 9 9	4/29/04	Castelhana et al.				
	14	20 05 00 43 3 3 2	2/24/05	Castelhana et al.				
	15	11 9 0 3 1 4 7	9/20/07	Castelhana et al.				
FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	16	9 7 4 7 6 0 1	12/18/97	PCT				
	17	9 9 6 4 4 0 7	12/16/99	PCT				
	18	9 9 0 8 4 6 0	2/18/99	PCT				
	19	0 0 0 3 7 4 1	1/27/00	PCT				
	20	20 03 05 3 3 6 1	7/3/03	PCT				
	21	20 03 05 3 3 6 6	7/3/03	PCT				
	22	0 7 2 9 7 5 8	9/4/96	EPO				
	23	1 2 4 6 6 2 3	8/9/06	EPO				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
	24	Hungarian Patent No. HU P9303515 (corresponds to WO 94/13676)						
	25	Hungarian Patent No. HU P9501230 (corresponds to EP 0682027)						
	26	Hungarian Patent No. HU P9602016 (corresponds to WO 95/19970)						
	27	Hungarian Patent No. HU P9402829 (corresponds to WO 93/20078)						
	28	Hungarian Patent No. HU P9602017 (corresponds to WO 95/19774)						
	29	Abbracchio M., et al., (1997) "Modulation of Apoptosis by Nervous System: a Possible Role for the A3 Receptor", <u>Ann. NY. Acad. Sci.</u> , 825: 11-22						
	30	Aoyama S. et al. (2000) "Rescue of Locomotor Impairment in Dopamine D2 Receptor-Deficient Mice by an Adenosine A2a Receptor Antagonist" <u>J. Neuroscience</u> 20(15) : 5848-5852						
	31	Avila, M.Y. (2001) "A1-A2a and A3-Subtype Adenosine receptors Modulate Intraocular Pressure in the Mouse" <u>J. of Pharmacol.</u> 241-245						
	32	Baraldi, P.G. et al. (1996) "Pyrazolo [4,3-e]-1,2,4 triazolo [1,5-c]pyrimidine Derivatives: Potent and Selective A2a Adenosine Antagonists" <u>J. Med. Chem.</u> 39: 1164-1171						
	33	Baraldi P., et al. (2000) "New potent and selective human adenosine A3 receptor antagonists", <u>Tips</u> , 21: 456-459						
	34	Baraldi P., et al. "Pyrazolo-triazolo-pyrimidine derivatives as adenosine receptor antagonists: a possible template for adenosine receptor subtypes", <u>Curr. Pharm. Design</u> 8: 2299-2332, 2002						
EXAMINER		/Alton Pryor/			DATE CONSIDERED 10/20/2008			
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>								

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.P./

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60390-1A/JPW/GJG/ML		Serial No. 10/718,280	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicants: Arlindo Castelhana et al.		Filing Date November 20, 2003	
U.S. PATENT DOCUMENTS								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
	35	Baraldi, P.G. et al., (1999) "A1 and A3 adenosine receptor agonists: an overview." <i>Expert Opinion on Therapeutic Patents</i> , 9(5):515-527						
	36	Baraldi, P.G. et al., (2004) "Allosteric modulators for the A1 adenosine receptor." <i>Expert Opinion on Therapeutic Patents</i> , 14(1):71-79						
	37	Baraldi, P.G. (2003) "Recent developments in the field of A2A and A3 adenosine receptor antagonists" <i>Eur. J. Med. Chem.</i> 38(4) 367						
	38	Blazynski C., (1990) "Discrete Distributions of Adenosine Receptors in Mammalian Retina", <i>Journal of Neurochemistry</i> , 53: 648-655						
	39	Borman, S. (2001) "A3 Receptors" <i>C&EN</i> , 79(7), 37						
	40	Braas K.M., et al., (1987) "Endogenous adenosine and adenosine receptors localized to ganglion cells of the retina", <i>Proceedings of the National Academy of Science</i> , 84: 3906-3910						
	41	Bradford M. M., (1976) "A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding", <i>Anal. Biochem.</i> , 72: 248						
	42	Bremer et al. (2002) "Therapy of Crohn's Disease in Childhood", <i>Expert Opin. Pharmacother.</i> 3(7): 809-825						
	43	Broach, J. R. et al., (1983) "Vectors for high level, inducible expression of cloned genes in yeast", Inouye (ed), <i>Experimental Manipulation of Gene Expression</i> , Academic Press, New York, 83-117						
	44	Casavola V., et al., (1983) "Adenosine A3 receptor activation increases cytosolic calcium concentration via calcium influx in A6 cells", <i>Drug Development Research</i> , 43 (1): 62						
	45	Cheng, Y. and Prusoff, W. H. (1973) "Relationship Between The Inhibition Constant (K _i) And The Concentration Of Inhibitor Which Causes 50 Per Cent Inhibition (I ₅₀) Of An Enzymatic Reaction", <i>Biochem. Pharmacol.</i> , 22: 3099-3109						
	46	Christianson, T. W. et al., (1992) "Multifunctional yeast high-copy-number shuttle vectors", <i>Gene</i> , 110: 119-122						
	47	Christofi, F. L. et al. (2001), "Differential Gene Expression of Adenosine A1, A2a, A2b, and A3 Receptors in the Human Enteric Nervous System", <i>J. Comp. Neurol.</i> 439(1): 46-64						
	48	Coney, A. M. et al. (1998) "Role of Adenosine and its Receptors in the Vasodilation Induced in the Cerebral Cortex of the Rat by Systemic Hypoxia" <i>J. Physiol.</i> 509: 507-518						
	49	Cooper, J. A. (1995) "Adenosine Receptor-induced Cyclic AMP Generation and Inhibition of 5-hydroxytryptamine release in Human Platelets" <i>Br. J. Clin. Pharmacol.</i> 40:43-50						
	50	Corset, V. et al. (2000), "Netrin-1-mediated axon outgrowth and cAMP production requires interaction with adenosine A2b receptor", <i>Nature</i> , 407 (6805): 747-750						
	51	Dubey, R. K. et al. (2001), "A2B Receptors Mediate the Antimitogenic Effects of Adenosine in Cardiac Fibroblasts", <i>Hypertension</i> 37: 716-721						
	52	Duzic, E. et al, (1992) "Factors Determining the Specificity of Signal Transduction by Guanine Nucleotide-binding Protein-coupled Receptors", <i>J. Biol. Chem.</i> , 267: 9844-9851						
	53	Ezeamuzie C., et al. (1999), <i>British Journal of Pharmacology</i> , 127: 188-194						
	54	Faivre, K. et al., (2001) "Suppression of Cellular Invasion by Activated G-Protein Subunits Gαo, Gαi1, and Gαi3 and Sequestration of Gβγ", <i>Mol. Pharmacol.</i> 60: 363-372						
	55	Feoktistov, I. and Biaggioni, I., (1997) "Adenosine A2B Receptors", <i>Pharmacol. Rev.</i> 49(4): 381-402						
EXAMINER		/Alton Pryor/			DATE CONSIDERED		10/20/2008	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.P./

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60390-1A/JPW/GJG/ML		Serial No. 10/718,280	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicants: Arlindo Castelhana et al.			
					Filing Date November 20, 2003		Group 1624	
U.S. PATENT DOCUMENTS								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
	56	Feoktistov, I. et al., (2002) "Differential Expression of Adenosine Receptors in Human Endothelial Cells", <i>Circulation Research</i> 90: 531-538						
	57	Fishman P (2003) "Pharmacology and therapeutic applications of A3 receptor subtype" <i>Curr. Top. Med. Chem.</i> 3(4): 463-9						
	58	Fozard J., et al., (1996) "Mast cell degranulation following adenosine A3 receptor activation in rats", <i>European Journal of Pharmacology</i> , 298: 293-297						
	59	Franco M., et al., (1999) "Adenosine Regulates Renal Nitric Oxide Production in Hypothyroid Rats", <i>Journal of the American Society of Nephrology</i> , 1681-1688						
	60	Gao, Z. et al., "A2B Adenosine and P2Y2 Receptors Stimulate Mitogen-activated Protein Kinase in Human Embryonic Kidney-293 Cells" <i>J. Bio. Chem.</i> (1999) 274(9): 5972-5980						
	61	Ghiardi, G. J. et al. (1999) "The Purine Nucleoside Adenosine in Retinal Ischemia-Reperfusion Injury" <i>Vision Research</i> 39:2519-2535						
	62	GenBank accession # S46950						
	63	GenBank accession numbers S45235 and S56143						
	64	Grant, M.B. et al., (2001) "Proliferation, Migration, and ERK Activation in Human Retinal Endothelial Cells through A2B Adenosine Receptor Stimulation", <i>Invest. Ophthalmol. Vis. Sci.</i> 42(9): 2068-2073						
	65	Guerra L., et al., (1998) "Adenosine A3 receptor activation increases cytosolic calcium influx in A6 cells", <i>Nephrology Dialysis Transplantation</i> , 13 (6): A5						
	66	Guo, Y. et al., (2001) "Targeted deletion of A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning." <i>J Mol Cell Cardiol</i> , 33:825-830						
	67	Haynes, J. Jr. et al., (1999) "5-(N-ethylcarboxamido) adenosine desensitizes the A2b-adenosine receptor in lung circulation", <i>Am. J. Physiol.</i> 276(6): H1877-H1883						
	68	Herndon, J.L. et al., (1992) Herndon, J.L. et al., "Ketanserin Analogs: Structure-Affinity Relationships for 5-HT2 and 5-HT1C Serotonin Receptor Binding", <i>J. Med. Chem.</i> 35(26): 4903-4910						
	69	Hoeschst India Ltd., India "Pharmacologically active pyrimido "[4,5-b]indoles and their salts." Database accession No. 106:84629 HCA XP002121648						
	70	Kanda, T. et al. (1998) "Adenosine A2a Receptors Modify Motor Function in MPTP-treated Common - Marmosets" <i>Neuroreport</i> 9: 2857-2860						
	71	Kanda, T. et al. (2000) "Combined Use of the Adenosine A2a Antagonist KW-6002 with L-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but not Dyskinesia in MPTP-Treated Monkeys" <i>Experimental Neurology</i> 162: 321-327						
	72	Kang, Y. et al., (1990) "Effects of Expression of Mammalian Gα and Hybrid Mammalian-Yeast Gα Proteins on the Yeast Pheromone Response Signal Transduction Pathway", <i>Mol. Cell. Biol.</i> , 10: 2582-2590						
	73	Kiichiro, K. et al. "Synthesis of pyrazinecarboxylic acid derivs. - (II) derivs. of 3-aminopyrazinecarboxylic acid" <i>Chem. Abstracts</i> 56:8713						
EXAMINER				DATE CONSIDERED				
/Alton Pryor/				10/20/2008				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.P./

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60390-1A/JPW/GJG/ML		Serial No. 10/718,280	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicants: Arlindo Castelbano et al.			
					Filing Date November 20, 2003			Group 1624
U.S. PATENT DOCUMENTS								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
	74	Kiritsy, J.A. et al., (1978) "Synthesis and Quantitative Structure-Activity Relationships of Some Antibacterial 3-Formylrifamycin SV N-(4-Substituted phenyl) piperazinoacethydrazones" J. Med. Chem. 21(12): 1301-1307						
	75	Klumpp, D.A. et al., (1999) "Synthesis of Aryl-Substituted Piperidines by Superacid Activation of Piperidones" J. Org. Chem. 64(18): 6702-6705						
	76	Knutsen, L.J.S. et al. (2001) <u>Curr. Opin. Invest. Drugs</u> 2(5):668-673						
	77	Kopf, S.R. et al. (1999) "Adenosine and Memory Storage: Effect of A1 and A2 Receptor Antagonists" <u>Psychopharmacology</u> 146:214-219						
	78	Li, J.M. et al. (1998) "Adenosine A2a Receptors Increase Arterial Endothelial Cell Nitric Oxide" <u>J. Surg. Res.</u> 80:357-364						
	79	Linden, J. et al., (1998) "The Structure and Function of A1 and A2B Adenosine Receptors" <u>Life Sciences</u> 62(17-18): 1519-1524						
	80	Meade et al., PubMed Abstract (Life Sci. 69(11):1225-40) August 2001						
	81	Mitchell, C.H. et al., "Adenosine A3 Receptor Activation Reduces Cell Volume and Activates Cl ⁻ Current in Human Ciliary Epithelial Cells", <u>FASEB J.</u> A134 (Abstract only)						
	82	Michell, C.H. (1999) "A3 adenosine receptors regulate Cl ⁻ -channels of nonpigmented ciliary epithelial cells" <u>Am. J. Physiol.</u> 276: C659-C666						
	83	Mirabet, M. et al., (1999) "Expression of A2B adenosine receptors in human lymphocytes: their role in T cell activation" <u>J. Cell. Sci.</u> 112(4): 491-502						
	84	Montesinos, M.C. et al. (2002) "Adenosine Promotes Wounds Healings and Mediates Angiogenesis in Response to Tissue Injury Via Occupancy of A2a Receptors" <u>American Journal of Pathology</u> 160(6):2009-2018						
	85	Müller, C.E. et al., "Imidazo [2,1-i] purin-5-ones and Related Tricyclic Water-Soluble Purine Derivatives: Potent A2A- and A3-Adenosine Receptor Antagonists", (2002) <u>J. Med. Chem.</u> 45(16): 3440-3450						
	86	Müller, C.E. (2001) "A3 Adenosine Receptor Antagonists" <u>Mini Reviews in Med. Chem.</u> 1(4): 339						
	87	Nagarathnam, D. et al., (1998) "Design and Synthesis of Novel α 1a Adrenoceptor-Selective Dihydropyridine Antagonists for the Treatment of Benign Prostatic Hyperplasia", <u>J. Med. Chem.</u> 41(26): 5320-5333						
	88	Nishiyama, A. et al. (2001) "Interactions of Adenosine A1 and A2 a Receptors on Renal Microvascular Reactivity" <u>Am. J. Physiol. Renal Physiol.</u> 280:F406-F414						
EXAMINER		/Alton Pryor/			DATE CONSIDERED			
					10/20/2008			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.P./

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60390-IA/JPW/GJG/ML		Serial No. 10/118,280	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicants: Arlindo Castelhana et al.			
					Filing Date November 20, 2003		Group 1624	
U.S. PATENT DOCUMENTS								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
89	Ohana G., et al., (2001) "Differential Effect of Adenosine on Tumor and Normal Cell Growth: Focus on the A3 Adenosine Receptor", <u>Journal of Cellular Physiology</u> , 186: 19-23							
90	Phillips, J.W. (1995) "The Effects of Selective A1 and A2a Adenosine Receptor Antagonists on Cerebral Ischemic Injury in the Gerbil							
91	Polosa (2002) "Adenosine-receptor subtypes: their relevance to adenosine-mediated responses in asthma and chronic obstructive pulmonary disease", <u>Eur. Respir. Journal</u> 20,488-496							
92	Priego, E.-M. et al., "Pyrido [2,1-f]purine-2,4-dione Derivatives as a Novel Class of Highly Potent Human A3 Adenosine Receptor Antagonists", (2002) <u>J. Med. Chem.</u> , 45(16): 3337-3344							
93	Ralevic, V. And Burnstock, G., (1998) "Receptors for Purines and Pyrimidines", <u>Pharmacol. Rev.</u> 50(3): 413-492							
94	Regnauld, K. et al., (2002) "G-protein α olf subunit promotes cellular invasion, survival, and neuroendocrine differentiation in digestive and urogenital epithelial cells", <u>Oncogene</u> 21(25): 4020-4031							
95	Regulation of Downstream Effectors By GPCRs, (1999) <u>FASEB J.</u> , Abstracts 147.1-147.6							
96	Reshkin J., et al., (2000) "Activation of A3 Adenosine Receptor Induces Calcium Entry and Chloride Secretion in A6 Cells", <u>J. Membrane Biol.</u> , 178: 103-113							
97	Robinson, "Medical Therapy of Inflammatory Bowel Disease for the 21st Century", <u>Eur J Surg. Suppl</u> 582:90-98, 1998							
98	Sawynok J., et al., (1997) "Adenosine A3 receptor activation produces nociceptive behaviour and edema by release of histamine and 5-hydroxytryptamine", <u>European Journal of Pharmacology</u> , 333: 1-7							
99	Shiozaki, S. et al. (1999) "Actions of Adenosine A2a Receptor Antagonist KW-6002 on Drug-induced Catalepsy and hypokinesia Caused by Reserpine of MPTP" <u>Psychopharmacology</u> 147:90-95							
100	Simone, <u>Oncology: Introduction Cecil Textbook of Medicine</u> , 20th Edition, Vol. 1, pp. 1004-1010, 1996							
101	Singh et al., "Immune therapy in inflammatory bowel disease and models of colitis", <u>British Journal of Surgery</u> , 88: 1558-1569, 2001							
102	Strohmeier, G. R. et al., (1995) "The A2b Adenosine Receptor Mediates cAMP Responses to Adenosine Receptor Agonists in Human Intestinal Epithelia", <u>J. Bio. Chem.</u> , 270: 2387-2394							
103	Svenningsson, P. et al. (1999) "Distribution, Biochemistry and Function of Striatal Adenosine A2a Receptors" <u>Prog. Neurobiol.</u> 59(4):355-396							
104	Tanaka, H. et al., "Preparation and formulation of fused pyrimidine compounds as CRF receptor antagonists." Database accession no. 129:109098 HCA XP002121647							
105	Taomoto, M. et al. (2000) "Localization of Adenosine A2 Receptor in Retinal Development and Oxygen-Induced Retinopathy" <u>Investigative Ophthalmology & Visual Science</u> 41(1):230-243							
106	Van Niel, M.B. et al., "Fluorination of 3-(3-(Piperidin-1-yl)propyl)indoles and 3-(3-(Piperazin-1-yl)propyl)indoles Gives Selective Human 5-HT ₂ Receptor Ligands with Improved Pharmacokinetic Profiles" <u>J. Med. Chem.</u> (1999) 42(12): 2087-2104							
107	Varani, K. et al. (1998) "[³ H]-SCH 58261 Labelling of Functional A2a Adenosine Receptors in Human Neutrophil Membranes" <u>Br. J. Pharmacol.</u> 123:1723-1731							
EXAMINER					DATE CONSIDERED			
/Alton Pryor/					10/20/2008			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.P./

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60390-1A/JPW/GJG/ML		Serial No. 10/718,280	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicants: Arlindo Castelbano et al.			
					Filing Date November 20, 2003		Group 1624	
U.S. PATENT DOCUMENTS								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
	108	Von Lubitz D., et al., (1999) "Stimulation of Adenosine A3 Receptors in Cerebral Ischemia", <u>Ann. NY. Acad. Sci.</u> , 890: 93-106						
	109	Von Lubitz, D., et al., (1999) "Chronic administration of adenosine A3 receptor agonist and cerebral ischemia: neuronal and glial effects", <u>European Journal of Pharmacology</u> , 367: 157-163						
	110	West, R.A. et al. (1961) "2-alkyl(aryl)-and 2,7-dimethyl-4-substituted aminopyrrolo[2,3-d]pyrimidines." <u>J. Org. Chem.</u> , 26:3809-3812						
	111	Yan, Luo et al. (2003) Expert Opinion on Emerging Drugs, vol. 8, no. 2 pp. 537-576						
	112	Yao Y., et al., (1997) "Adenosine A3 Receptor Agonists Protect HL-60 and U-937 Cells from Apoptosis Induced by A3 Antagonists", <u>Biochemical And Biophysical Research Communications</u> , 232: 317-322						
	113	Zhao Z., et al., (2000) "A role for the A3 Adenosine receptor in determining tissue levels of cAMP and blood pressure: studies in knock-out mice", <u>Biochimica et Biophysica Acta</u> , 1500: 280-290						
	114	International Search Report issued in PCT International Application No. PCT/US99/12135, filed June 1, 1999						
	115	International Search Report issued in PCT International Application No. PCT/US00/32702, filed December 1, 2000						
	116	International Search Report issued in PCT International Application No. PCT/US2001/045280, filed November 30, 2001						
	117	International Search Report issued in PCT International Application No. PCT/US2002/38055, filed November 27, 2002						
	118	International Search Report issued in PCT International Application No. PCT/US2002/40890, filed December 20, 2002						
	119	International Search Report issued in PCT International Application No. PCT/US2002/41273, filed December 20, 2002						
	120	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US99/121358						
	121	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US00/32702						
	122	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US2001/045280, filed November 30, 2001						
	123	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US2002/38055, filed November 27, 2002						
	124	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US2002/40890, filed December 20, 2002						
	125	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US2002/41273, filed December 20, 2002						
	126	Supplemental European Search Report; for EP Application No. 02 80 5676; issued 2/7/2005						
	127	Partial European Search Report for EP Application No. 06 01 6543.8; completed 10/4/2006						
	128	Partial European Search Report; for EP Application No. 01 99 7029; completed 12/21/2004						
EXAMINER /Alton Pryor/				DATE CONSIDERED 10/20/2008				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

